High expression of RRM1 and ERCC1 predicts longer survival after surgery in lung cancer
This article has no abstract so we have provided the first paragraph of the full text.
Low expression of RRM1 (the regulatory subunit of ribonucleotide reductase) has been associated with worse survival in non-small-cell lung cancer (NSCLC). In this recent paper, Zheng et al. report a simple automated immunohistochemical assay for detection of RRM1 protein. Their study of 187 patients with NSCLC who had undergone complete tumor resection without having received preoperative chemotherapy or radiotherapy highlights the potential prognostic utility of RRM1 expression in this setting.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.